Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis

Eur J Gastroenterol Hepatol. 2018 Dec;30(12):1395-1405. doi: 10.1097/MEG.0000000000001198.

Abstract

The association between the long-term use of proton pump inhibitors (PPIs) and the risks of various diseases remains controversial. Therefore, the primary objective of this study was to quantify the associations as presented in the literature and to also provide this information to healthcare professionals and patients about their potentially adverse effects. In July 2016, we searched through Medline (PubMed), Embase, and the Cochrane Library from inception using common keywords. We included observational studies that provided risk estimates on the long-term use of PPIs and their adverse effects. Overall, 43 studies were included in the systematic review, of which 28 studies were also included in the random effect meta-analysis. Odds of community-acquired pneumonia, hip fracture, and colorectal cancer were 67% [odds ratio (OR)=1.67; 95% confidence interval (CI): 1.04-2.67], 42% (OR=1.42; 95% CI: 1.33-1.53), and 55% (OR=1.55; 95% CI: 0.88-2.73) higher in patients with long-term PPIs use compared with patients who did not use PPIs. Although the use of PPIs provides short-term health benefits, their prolonged use is associated with minor and also potentially major adverse health outcomes. Hence, we strongly recommend that the prescription of PPIs should be done with caution to improve the medication's efficacy and patients' safety.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Colorectal Neoplasms / chemically induced
  • Colorectal Neoplasms / epidemiology
  • Community-Acquired Infections / chemically induced
  • Community-Acquired Infections / epidemiology
  • Hip Fractures / chemically induced
  • Humans
  • Pneumonia / chemically induced
  • Pneumonia / epidemiology
  • Proton Pump Inhibitors / adverse effects*
  • Risk Assessment / methods

Substances

  • Proton Pump Inhibitors